Skip to main content

CARACTERIZACION Y FACTORES DE RIESGO DE LAS SECUELAS PULMONARES DE LOS PACIENTES QUE SUPERAN UNA NEUMONIA POR COVID-19 (PULSE-COVID).

PI21/01046

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre HOSPITAL VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acquired tracheomalacia due to SARS-CoV-2 pneumonia

  • Espejo Castellanos, David
  • Zapata-Ortega, Marta
  • Omari, Saliha
  • Muñoz Gall, Francisco Javier|||0000-0002-8693-022X
  • Cruz, María Jesús|||0000-0001-9759-5466
Several studies mentioned parenchymal findings after SARS-CoV-2 pneumonia, but few studies have mentioned alterations in the airways. The aim of this study was to estimate the prevalence of tracheomalacia and to analyse the clinical characteristics in a cohort of patients with SARS-CoV-2. The study population consisted of all patients with SARS-CoV-2 admitted a hospital serving a population of 500 000 inhabitants. Patients were visited between 2 and 6 months after hospital discharge. In this visit, all patients were subjected to an exhaustive clinical questionnaire and underwent clinical examination, pulmonary function tests and chest CT. From February 2020 to August 2021, 1920 patients were included in the cohort and tracheomalacia was observed in 15 (0.8%) on expiratory HRCT imaging. All patients with tracheomalacia also presented ground glass opacities in the CT scan and 12 patients had airway sequelae. Tracheomalacia is an exceptional sequela of SARS-CoV-2 survivors.